CVS Health has launched Transform Diabetes Care, its new program set up to assist pharmacy benefits management clients in the improvement of member health outcomes, to decrease costs with aggressive trend management, and to cut medical costs by refining medication adherence. Read More »
Merck continued its release of KEYTRUDA results by reporting that its Phase 3 KEYNOTE-024 clinical trial demonstrated positive health-related quality of life. Read More »
Eiger BioPharmaceuticals has announced clinical and regulatory development advancements of exendin 9-39, which was developed to treat post-bariatric hypoglycemia. Read More »
Merck has released updated data from two clinical trials designed to assess KEYTRUDA (pembrolizumab), its anti-PD-1 therapy developed to treat patients who have relapsed or refractory classical Hodgkin lymphoma (cHL). Read More »
Merck recently released updated data from its Phase 1b KEYNOTE-028 clinical trial, which involved KEYTRUDA. Read More »
Endo International plc subsidiary Par Pharmaceutical has released mycophenolate mofetil hydrochloride as an injection in the United States after the Food and Drug Administration gave its approval of Endo’s Abbreviated New Drug Application. Read More »
Pfizer and its partner Avillion LLP have announced the results from the BFORE clinical study. Read More »
Sandoz's generic version of Latisse, bimatoprost ophthalmic solution, 0.03 percent, is now available in the United States. Read More »
Baxter International Inc. has once again earned the highest possible score of 100 percent on the 2017 Corporate Equality Index, which is produced by the Human Rights Campaign Foundation. Read More »
Endo International and BioDelivery Sciences International (BDSI) have agreed to return the BELBUCA buccal film product to BDSI. Read More »
Kite Pharma recently presented the results of its ZUMA-1 clinical trial involving axicabtagene ciloleucel (KTE-C19) at the American Society of Hematology (ASH) 58th Annual Meeting. Read More »
Voluntis has received FDA 510(k) clearance for Insulia, which also received the CE Mark for the treatment of Type 2 diabetes in adult patients that have had previous basal insulin treatments. Read More »
CTI BioPharma Corp.'s data from its PERSIST-2 Phase 3 clinical study was presented as a late-breaking oral session at the 58th American Society of Hematology Annual Meeting, which was held in San Diego Dec. 3-6. Read More »
The CVS Health Institute and the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response recently released research showing that automated notifications sent out by pharmacies are helping patients with chronic conditions remember to refill their medications before forecast natural disasters hit. Read More »
As National Influenza Vaccination Week runs through Saturday, CVS Pharmacy is reminding families across the U.S. that it is not too late to get their flu shots. Read More »
Rite Aid has announced that their customers will be able to save $5 on flu shots during National Influenza Vaccination Week in support of the cause. Read More »
Amgen presented data from its Phase 3 TOWER study at the 58th Annual Meeting and Exposition of the American Society of Hematology this week in San Diego. Read More »
OptumRx and CVS Pharmacy say their collaboration that will provide improved health outcomes that are cost-efficient for consumers and clients while giving them more suitable choices. Read More »
Eisai Inc. has released the final results of its Phase 3 rufinamide study, an open-label, two-year investigation. Read More »
Cigna will be implementing an integrated hi-tech/hi-touch approach when it comes to the support and service of its customers. Read More »
Alerts Sign-up
